Savara to Host First Quarter 2018 Financial Result
Post# of 617763
AUSTIN, TX --(Marketwired - May 01, 2018) - Savara Inc. (
Shareholders and other interested parties may access the conference call by dialing (855) 239-3120 from the U.S., (855) 669-9657 from Canada, and (412) 542-4127 from elsewhere outside the U.S. and requesting the Savara Inc. call. A live webcast of the conference call will be available online in the Investors section of Savara's website at http://www.savarapharma.com/investors/events/ . Replays of the webcast will be available on Savara's website for 30 days and a telephone replay will be available through May 16 th , 2018 by dialing (877) 344-7529 from the U.S., (855) 669-9658 from Canada, and (412) 317-0088 from elsewhere outside the U.S. and entering replay access code 10119917.
About Savara Savara Inc. is an orphan lung disease company. Savara's pipeline comprises: Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for PAP, and in Phase 2a development for NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of MRSA infection in cystic fibrosis. Savara's strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara's management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization. More information can be found at www.savarapharma.com . (Twitter: @SavaraPharma )
Contacts: Savara: Ioana C. Hone ( ir@savarapharma.com ) (512) 961-1891 For IR: Solebury Trout Gitanjali Jain Ogawa ( Gogawa@troutgroup.com ) (646) 378-2949 For Media: Neon Interactive Patrick Wallace ( patrick@neoninteractive.com ) (619) 200-7856
(0)
(0)